Immatics and Editas partner on gene editing and T cells; Eyenovia founder to step down from CEO position
Two companies deeply involved in gene editing and T-cells are coming together in a new deal.
Immatics and Editas Medicine announced Tuesday that they have entered into a research and licensing agreement. The deal will seek to combine gamma-delta T cell adoptive cell therapies and gene editing to develop medicines for cancer treatment. As part of the licensing agreement, Immatics gains non-exclusive rights to Editas Medicine’s CRISPR technology and intellectual property.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.